Predictive factors of actual 5‐y recurrence‐free survival after upfront surgery for resectable pancreatic cancer

Masao Uemura,Teiichi Sugiura,Ryo Ashida,Katsuhisa Ohgi,Mihoko Yamada,Shimpei Otsuka,Takeshi Aramaki,Akifumi Notsu,Katsuhiko Uesaka
DOI: https://doi.org/10.1002/ags3.12834
2024-06-15
Annals of Gastroenterological Surgery
Abstract:Neoadjuvant treatment (NAT) for resectable pancreatic cancer (R‐PC) is the standard treatment in Japan, but some patients may not require NAT. This study investigated the prognostic factors associated with actual 5‐y recurrence‐free survival after upfront surgery for R‐PC. Since only ~10% of 5‐y recurrence‐free survivors could be identified preoperatively with two models, almost all R‐PC patients are forced to undergo NAT in daily practice. Aim The present study investigated the prognostic factors associated with actual 5‐y recurrence‐free survival (RFS) after upfront surgery for resectable pancreatic cancer (R‐PC) in patients who were deemed not to require neoadjuvant treatment. Methods Between 2007 and 2016, 316 patients who underwent pancreatectomy for radiologically R‐PC were retrospectively reviewed to evaluate the predictors of actual 5‐y RFS. Predictors were identified using logistic regression analysis of preoperative evaluable factors. The cutoff values for continuous variables were determined based on a minimum p‐value approach (model 1) or the value that maximized the rate of 5‐y RFS survivors (model 2). Results Fifty‐one patients (16.1%) achieved a 5‐y RFS. A tumor size ≤23 mm, the absence of serosal invasion on computed tomography (CT), and Neutrophil‐to‐Lymphocyte Ratio <1.0, were significantly associated with the 5‐y RFS in model 1. A Prognostic Nutritional Index ≥58 and the absence of serosal invasion and extrapancreatic nerve plexus invasion on CT were significantly associated with 5‐y RFS in model 2. Only six (11.8%, model 1) and four (7.8%, model 2) patients had all three prognostic factors, and their 5‐y RFS rates were 83.3% and 100%, respectively. Conclusions A modest number of patients who underwent upfront surgery achieved 5‐y RFS, but only ~10% of them could be identified preoperatively. Based on these results, almost all R‐PC patients are forced to undergo neoadjuvant treatment in daily practice.
gastroenterology & hepatology
What problem does this paper attempt to address?